Marketing In Brief
This article was originally published in The Rose Sheet
Executive Summary
Jan Marini Skin Research: San Jose, Calif. company launches Age Intervention Enlighten, "a remarkable new composition that brightens and encourages the uniform appearance of facial discoloration - even stubborn pigmentation," according to May 6 release. President and CEO Jan Marini states: "Women often associate fine lines and wrinkles with aging, but discoloration is an even more visual sign of the aging process." Product, available in 1-oz. pump, addresses facial discoloration due to melasma, cumulative sun exposure and ethnicity with two topical agents and anti-aging Retinol, awarding "more refined, rejuvenated and illuminated skin," according to company. In January, JMSR suspended sales of two Age Intervention eyelash products in the U.S. due to uncertain regulatory environment and pressure from pharma giant Allergan, which claimed its patent had been infringed. Marketed as a means of conditioning lashes and improving their volume, texture and density, the products had brought in roughly 30 percent of the company's domestic sales prior to suspension (1"The Rose Sheet" Jan. 14, 2008, p. 8)...
You may also be interested in...
Jan Marini Ceases Eyelash Product Sales Due To Allergan Suit, FDA Threat
Jan Marini Skin Research (JMSR) is suspending sales of its two Age Intervention eyelash products in the U.S. - citing an uncertain regulatory environment and the daunting prospect of litigation - and focusing on its core skin-care line and opportunities abroad
OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"
With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program
Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands
Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle